![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Grants Orphan Designation to Samumed’s IPF Treatment
FDA Grants Orphan Designation to Samumed’s IPF Treatment
![FDA_Logo_Black_2016.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Black_2016.gif?t=1579040596&width=430)
The FDA granted Samumed an Orphan Drug designation for its SM04646 compound for idiopathic pulmonary fibrosis, a chronic disorder that causes deteriorating lung function.
The drug is administered locally via a nebulizer and has the potential to be used as a monotherapy or in combination with currently approved oral medications, Esbriet (pirfenidone) or Ofev (nintedanib).
Samumed recently completed a Phase I study in healthy subjects, with SM04646 appearing to be safe and well tolerated.
Upcoming Events
-
21Oct